Patent search ap:("ABBOTT LAB") AND inv:"GONG JIANCHUN" Page 7

61.

发明专利
Reverse hydroxamate inhibitors of matrix metalloproteinases 未知

公开(公告)号：AU758870B2

公开(公告)日：2003-04-03

申请号：AU8513998

申请日：1998-07-27

Applicant: ABBOTT LAB

Inventor： CURTIN MICHAEL L , DAVIDSEN STEVEN K , DELLARIA JOSEPH F , FLORJANCIC ALAN S , GIESLER JAMIE , GONG JIANCHUN , GUO YAN , HEYMAN H ROBIN , HOLMS JAMES H , MICHAELIDES MICHAEL R , STEINMAN DOUGLAS H , WADA CAROL K , XU LIANHONG

IPC: C07D233/74 , A61K31/275 , A61K31/351 , A61K31/352 , A61K31/4035 , A61K31/4166 , A61K31/4178 , A61K31/421 , A61K31/428 , A61K31/4439 , A61K31/4465 , A61K31/45 , A61K31/454 , A61K31/50 , A61P1/02 , A61P1/04 , A61P19/02 , A61P19/10 , A61P29/00 , A61P35/00 , A61P43/00 , C07C259/06 , C07C311/05 , C07C311/18 , C07C317/28 , C07C317/40 , C07C323/47 , C07C323/62 , C07D207/40 , C07D207/404 , C07D207/416 , C07D209/48 , C07D211/88 , C07D213/68 , C07D233/76 , C07D233/78 , C07D237/14 , C07D263/44 , C07D275/04 , C07D275/06 , C07D309/14 , C07D311/18 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07C259/00

Abstract: Compounds having formula (I) are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

62.

发明专利
N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES 未知

公开(公告)号：CA2294171A1

公开(公告)日：1999-02-11

申请号：CA2294171

申请日：1998-07-27

Applicant: ABBOTT LAB

Inventor： FLORJANCIC ALAN S , MICHAELIDES MICHAEL R , GIESLER JAMIE , GONG JIANCHUN , DAVIDSEN STEVEN K , STEINMAN DOUGLAS , HEYMAN H ROBIN , DELLARIA JOSEPH F JR , CURTIN MICHAEL L , WADA CAROL K , HOLMS JAMES H , XU LIANHONG , GUO YAN

IPC: C07D233/74 , A61K31/275 , A61K31/351 , A61K31/352 , A61K31/4035 , A61K31/4166 , A61K31/4178 , A61K31/421 , A61K31/428 , A61K31/4439 , A61K31/4465 , A61K31/45 , A61K31/454 , A61K31/50 , A61P1/02 , A61P1/04 , A61P19/02 , A61P19/10 , A61P29/00 , A61P35/00 , A61P43/00 , C07C259/06 , C07C311/05 , C07C311/18 , C07C317/28 , C07C317/40 , C07C323/47 , C07C323/62 , C07D207/40 , C07D207/404 , C07D207/416 , C07D209/48 , C07D211/88 , C07D213/68 , C07D233/76 , C07D233/78 , C07D237/14 , C07D263/44 , C07D275/04 , C07D275/06 , C07D309/14 , C07D311/18 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07C259/00 , C07D249/12 , A61K31/16 , A61K31/35 , A61K31/357 , C07D209/40 , A61K31/40 , A61K31/4164 , A61K31/42 , A61K31/44 , A61K31/445

Abstract: Compounds having formula (I) are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

63.

发明专利
Reverse hydroxamate inhibitors of matrix metalloproteinase 未知

公开(公告)号：ZA986828B

公开(公告)日：1999-01-29

申请号：ZA986828

申请日：1998-07-30

Applicant: ABBOTT LAB

Inventor： CURTIN MICHAEL L , DAVIDSEN STEVEN K , DELLARIA JOSEPH F JR , FLORJANCIC ALAN S , GIESLER JAMIE R , GONG JIANCHUN , GUO YAN , HEYMAN H ROBIN , HOLMS JAMES H , MICHAELIDES MICHAEL R , STEINMAN DOUGLAS H , WADA CAROL K , XU LIANHONG

IPC: C07D233/74 , A61K31/275 , A61K31/351 , A61K31/352 , A61K31/4035 , A61K31/4166 , A61K31/4178 , A61K31/421 , A61K31/428 , A61K31/4439 , A61K31/4465 , A61K31/45 , A61K31/454 , A61K31/50 , A61P1/02 , A61P1/04 , A61P19/02 , A61P19/10 , A61P29/00 , A61P35/00 , A61P43/00 , C07C259/06 , C07C311/05 , C07C311/18 , C07C317/28 , C07C317/40 , C07C323/47 , C07C323/62 , C07D207/40 , C07D207/404 , C07D207/416 , C07D209/48 , C07D211/88 , C07D213/68 , C07D233/76 , C07D233/78 , C07D237/14 , C07D263/44 , C07D275/04 , C07D275/06 , C07D309/14 , C07D311/18 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07C , C07D , A61K

Abstract: Compounds having formula (I) are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

64.

发明专利
未知

公开(公告)号：BRPI0722070A2

公开(公告)日：2014-04-08

申请号：BRPI0722070

申请日：2007-12-20

Applicant: ABBOTT LAB

Inventor： GANDHI VIRAJ B , GIRANDA VINCENT L , GONG JIANCHUN , PENNING THOMAS D , ZHU GUI-DONG

IPC: A01N43/58 , A61K31/495 , A61K31/50

Abstract: A compound selected from the group consisting of 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)pyrrolidine-2,5-dione and 4-(3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one, or a pharmaceutically acceptable salt thereof, for use in treating leukemia, colon cancer, glioblastomas, lymphomas, melanomas, carcinomas of the breast or cervical carcinomas in a mammal by administering thereto a therapeutically acceptable amount of said compound.

65.

发明专利
1H-benzimidazol-4-carboxamidas sustituidas con un carbono cuaternario en la posición 2 como inhibidores de PARP para su uso en el tratamiento del cáncer 未知

公开(公告)号：ES2426981T3

公开(公告)日：2013-10-28

申请号：ES11189346

申请日：2006-04-11

Applicant: ABBOTT LAB

Inventor： ZHU GUIDONG , GONG JIANCHUN , GANDHI VIRAJKUMAR B , PENNING THOMAS D , GIRANDA VINCENT

IPC: A61K31/4184 , A61K31/454 , A61K31/55 , A61P9/10

Abstract: Un compuesto de Fórmula (I),**Fórmula** o una sal terapéuticamente aceptable del mismo, para su uso en el tratamiento de cáncer en un mamífero con unanecesidad reconocida de dicho tratamiento, donde R1, R2, y R3 se seleccionan independientemente entre el grupo que consiste en hidrógeno, alquenilo, alcoxi,alcoxicarbonilo, alquilo, alquinilo, ciano, haloalcoxi, haloalquilo, halógeno, hidroxi, hidroxialquilo, nitro, NRARB y(NRARB)carbonilo; A es R5 se selecciona independientemente entre el grupo que consiste en alquenilo, alcoxi, alcoxicarbonilo, alquilo,alquinilo, haloalcoxi, haloalquilo, halógeno, hidroxi, hidroxialquilo, NRCRD, y (NRCRD)carbonilo; n es 0, 1, 2 o 3; R6 se selecciona entre el grupo que consiste en hidrógeno, alquenilo, alcoxialquilo, alcoxicarbonilo,alcoxicarbonilalquilo, alquilo, alquinilo, arilo, arilalquilo, cicloalquilo, cicloalquilalquilo, heterociclo,heterocicloalquilo, heteroarilo, heteroarilalquilo, hidroxialquilo, (NRCRD)alquilo, (NRCRD)carbonilo,(NRCRD)carbonilalquilo y (NRCRD)sulfonilo; RA y RB se seleccionan independientemente entre el grupo que consiste en hidrógeno, alquilo y alquilcarbonilo; yRC y RD se seleccionan independientemente entre el grupo que consiste en hidrógeno y alquilo.

66.

发明专利
1H-benzimidazol-4-carboxamider substitueret med et kvaternært carbon i 2-stillingen som PARP-inhibitorer til anvendelse ved behandling af cancer 未知

公开(公告)号：DK2420234T3

公开(公告)日：2013-10-21

申请号：DK11189346

申请日：2006-04-11

Applicant: ABBOTT LAB

Inventor： ZHU GUIDONG , GONG JIANCHUN , GANDHI VIRAJKUMAR B , PENNING THOMAS D , GIRANDA VINCENT

IPC: A61K31/4184 , A61K31/454 , A61K31/55 , A61P9/10

67.

发明专利
1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS 未知

公开(公告)号：RS52546B

公开(公告)日：2013-04-30

申请号：RSP20120464

申请日：2006-04-11

Applicant: ABBOTT LAB

Inventor： ZHU GUIDONG , GONG JIANCHUN , GANDHI VIRAJKUMAR B , PENNING THOMAS D , GIRANDA VINCENT

IPC: C07D401/04 , A61K31/4184 , A61K31/454 , C07D403/04

Abstract: Compounds of Formula (I) (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).

68.

发明专利
1H-BENZIMIDAZOL-4-KARBOKSAMIDI SUPSTITUIRANI S KVATERNARNIM UGLJIKOM NA 2-POLOŽAJU KAO POTENTNI PARP INHIBITORI 未知

公开(公告)号：HRP20120819T1

公开(公告)日：2012-11-30

申请号：HRP20120819

申请日：2012-10-11

Applicant: ABBOTT LAB

Inventor： ZHU GUIDONG , GONG JIANCHUN , GANDHI VIRAJKUMAR B , PENNING THOMAS D , GIRANDA VINCENT

IPC: C07D401/04 , A61K31/4184 , A61K31/454 , C07D403/04

69.

发明专利
Las 1H-bencimidazol-4-carboxamidas substituidas son potentes inhibidores de la PARP 未知

公开(公告)号：ES2385849T3

公开(公告)日：2012-08-01

申请号：ES07761722

申请日：2007-05-02

Applicant: ABBOTT LAB

Inventor： GIRANDA VINCENT L , PENNING THOMAS D , GANDHI VIRAJKUMAR B , THOMAS SHEELA A , ZHU GUI-DONG , GONG JIANCHUN

IPC: C07D403/10 , A61K31/4184 , A61P29/00 , A61P37/00 , C07D235/18 , C07D409/04

Abstract: Un compuesto de Formula (I)**Fórmula**o una sal terapeuticamente aceptable del mismo, dondeR1, R2 y R3 son independientemente seleccionados entre el grupo consistente en hidrogeno y halogeno;Ar1 es arilo, donde Ar1 esta eventualmente substituido con halogeno;X1 es alquilenilo;Z es heterociclo, donde Z esta sustituido con 1, 2, 3 o 4 substituyentes seleccionados entre el grupo consistente enalcoxialquilo, haloalquilo, hidroxialquilo, NRCRD y NRCRDalquilo; yRC y RD son independientemente seleccionados entre el grupo consistente en hidrogeno, alquilo, cicloalquilo ycicloalquilalquilo,a condicion de que, cuando Z sea un anillo no aromatico de 5 o 6 miembros que contiene 1 o 2 atomos de nitrogenoy eventualmente un atomo de azufre u oxigeno, entonces Z no este unido a X1 a traves de un atomo de carbono.

70.

发明专利
INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE 未知

公开(公告)号：NZ577348A

公开(公告)日：2012-04-27

申请号：NZ57734807

申请日：2007-12-20

Applicant: ABBOTT LAB

Inventor： GANDHI VIRAJ B , GIRANDA VINCENT L , GONG JIANCHUN , PENNING THOMAS D , ZHU GUI-DONG

IPC: A01N43/58 , A61K31/495 , A61K31/50 , C07D237/32 , C07D403/10

Abstract: Disclosed is a poly(ADP-ribose)polymerase compound of formula (Ik), wherein the substituents are as defined within the specification. An example of a compound of formula (Ik) includes 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)pyrrolidine-2,5-dione. Further disclosed is a pharmaceutical composition comprising a compound of formula (Ik), and the use of a compound of formula (Ik) for treating cancer and reducing tumour volume.

Search Results

Country/Region

Patent validity

Application date

Publication (announcement) day

applicant

The country/region where the applicant is located

Inventor

IPC

IPC Department

IPC class

IPC subclass

IPC group

IPC team

Appearance classification